63870-39-3 Usage
General Description
(5-Amino-1H-1,2,4-triazol-3-yl)methanol is a chemical compound with the molecular formula C3H6N4O. It is a derivative of 1,2,4-triazole and contains both an amino group and a hydroxyl group. (5-AMINO-1H-1,2,4-TRIAZOL-3-YL)METHANOL is used in pharmaceutical and chemical research as a building block for the synthesis of various biologically active compounds, including potential drug candidates. Its structure and reactivity make it a versatile intermediate in organic chemistry, allowing for the modification and functionalization of the triazole ring to tailor its properties for specific applications. Additionally, it may also be used as a reagent in organic synthesis and as a component in the preparation of coordination compounds in coordination chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 63870-39-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,3,8,7 and 0 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 63870-39:
(7*6)+(6*3)+(5*8)+(4*7)+(3*0)+(2*3)+(1*9)=143
143 % 10 = 3
So 63870-39-3 is a valid CAS Registry Number.
InChI:InChI=1/C3H6N4O/c4-3-5-2(1-8)6-7-3/h8H,1H2,(H3,4,5,6,7)
63870-39-3Relevant articles and documents
INHIBITORS OF HEPATITIS C VIRUS POLYMERASE
-
Page/Page column 101, (2012/06/30)
The present invention provides, among other things, compounds represented by the general Formula (I) and pharmaceutically acceptable salts thereof, wherein X, Y, R1A, R1B, R2, and R3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.
Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
-
Page/Page column 144, (2008/06/13)
The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
